Source: yahoo_news
Source ID: yahoo:3c38e618f018a9f161e7196b50f63bb8:MDWD
URL: https://finance.yahoo.com/healthcare/articles/independent-dsmb-recommends-mediwound-escharex-110000899.html?.tsrc=rss
Symbol: (MDWD)
Published: 2026-09-14 07:00:00 EDT
Time precision: minute
Title: Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027 YAVNE, Israel, September 14, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the independent Data and Safety Monitoring Board (DSMB)